Voluntary announcement - abbisko therapeutics announces positive preliminary phase II results with lavengratinib (ABSK061) for the treatment of achondroplasia
Filed with HKEX · Stock code 2256 · · 3 pages · English
Abbisko Cayman Limited 和譽開曼有限責任公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2256) VOLUNTARY ANNOUNCEMENT ## ABBISKO THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY ## PHASE II RESULTS WITH LAVENGRATINIB (ABSK061) FOR THE TREATMENT OF ACHONDROPLASIA Abbisko Cayman Limited (the “Company”, together with its subsidiaries, the “Group”) hereby informs the shareholders and pote
Earlier from Abbisko Cayman
- Poll results of the extraordinary general meeting held on September 17, 2026
- AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
- Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
- Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
- Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
Later from Abbisko Cayman
- 2026 Interim report
- Next Day Disclosure Returns
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Abbisko Cayman into a list and get an email when it puts out news.
Follow Abbisko Cayman